tbuckley/cabot-search huggingface dataset:
Ohrenheilkunde für den Praktischen Arzt.
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Renal effects of demeclocycline
Authors: M. Geheb
Journal: JAMA (1980)

Demeclocycline inhibits the hydroosmotic effect of antidiuretic hormone (ADH) in humans<sup>1</sup>and in the toad urinary bladder,<sup>1,2</sup>the latter a classic in vitro model of the mammalian distal nephron. This effect is responsible for the development of a dose-dependent, reversible form of nephrogenic diabetes insipidus in humans<sup>1</sup>and for the therapeutic efficacy of demeclocycline in the treatment of the chronic hyponatremia associated with the syndrome of inappropriate ADH secretion.<sup>3,4</sup>Demeclocycline has also been used to treat the hyponatremia often associated with pathologic edema-forming states, in which high circulating levels of ADH may contribute to the water retention characteristic of the severe forms of these disorders. Thus, in some patients with cirrhosis<sup>5-7</sup>or congestive heart failure,<sup>8-10</sup>demeclocycline causes a water diuresis and amelioration of the hyponatremia. The development of nephrogenic diabetes insipidus in these patients was predictable; what was not expected was the frequent development of
Plastic surgery
Authors: D. Serafin
Journal: JAMA (1979)

During the past decade, the specialty of plastic surgery has contributed to notable advances in microsurgery, craniofacial surgery, hand surgery, and other difficult reconstructive problems. Important contributions have also been made in the design and use of musculocutaneous flaps and to pioneering efforts in breast reconstruction for mastectomy patients. Emphasis is also being directed to the contralateral breast because of its recognized premalignant potential. <h3>Microsurgery</h3> With the advent of small-vessel anastomosis in the 1960s, it became possible to anastomose vessels as narrow as 1.0 mm in external diameter, with predictable patency rates. Reports soon appeared in the world literature describing the successful replantation of digits and even entire limbs. Many investigators were encouraged to review the physiology of the microcirculation and to investigate factors that influenced the viability of transferred tissue. Successful replantation efforts permitted innovative surgeons to review existing methods of reconstruction and to recognize their limitations. In 1972
Hypertension following renal transplantation. Causative factors and therapeutic implications
Authors: P. K. Whelton
Journal: JAMA (1979)

During a five-year period, we studied 21 of 319 renal transplant recipients who were admitted for evaluation of refractory hypertension. For comparison we examined 93 consecutive patients in the renal transplant clinic. Hypertension, which was noted in 47% of the outpatients, occurred with greater frequency following renal transplantation from cadaveric donors and was associated with a decline in renal function. The 21 inpatients had higher blood pressures and were studied at an earlier stage than their outpatient counterparts. Fourteen of the inpatients had underlying stenosis of their transplant artery and revascularization of the transplanted kidney was possible in the majority of these patients. Stenosis of the transplant artery was suggested by the occurrence of severe hypertension during the first year following transplantation, a bruit in the transplant region, and increased levels of peripheral plasma renin activity. (<i>JAMA</i>241:1128-1131, 1979)
Contribution of Lead in Dust to Children's Blood Lead
Authors: Michael J. Duggan
Journal: Environmental Health Perspectives (1983)

The importance of urban dust as a source of lead for young children is still disputed. Although blood-lead data from various population surveys usually show a peak concentration in early childhood, there is evidence that such a peak is small or absent altogether in children without much access to the general environment. An examination of those studies where groups of people in regions of low and high lead contamination have been compared shows that the child/adult blood-lead ratio is almost always enhanced in the more exposed groups. This implies a route of lead uptake which is important for children but less so for adults, and it is likely that this route is the dust-hand-mouth one. There are sufficient data to suggest a quantitative relationship between raised levels of blood lead and lead in dust. There is a strong case for a lead-in-dust standard but some will probably remain unpersuaded unless or until there are reliable data for blood lead and environmental lead involving matched groups of young people from urban and rural areas.
Educating physicians in home health care. Council on Scientific Affairs and Council on Medical Education [corrected]
Journal: JAMA (1991)

A growing proportion of health care, especially long-term care, should best and most appropriately be provided in the home setting. Physicians have largely remained on the periphery of this reemerging area of health care. Yet if home health care is to reach its full potential, physicians must fulfill their essential role as members of the home health team. Direct physician input and participation are needed to ensure that home health care is safe and medically appropriate. Physician involvement will enhance the supervision of medical care in the home, and physicians' expertise is also much needed for home health care quality assurance and clinical research. Role models and training experiences must be developed for new physicians so that they can integrate home health care skills and values into their future practices. Although most of the usual physician objections to home health care involvement can be addressed by education, the problem of inadequate reimbursement is substantive and must be addressed by policy change.
Modern Materia Medica, with Therapeutic Notes for the Use of Practitioners and Students of Medicine.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hormone Replacement Following Early Menopause
Authors: G. S. Cooper
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
De-adoption of epidermal growth factor receptor (EGFR) inhibitors following recommendations for KRAS testing to guide treatment of metastatic colorectal cancer (mCRC).
Authors: Efrat Dotan, Tianyu Li, Michael J. Hall, Neal J. Meropol, Robert J. Beck, Yu-Ning Wong
Journal: Journal of Clinical Oncology (2012)

191 Background: KRAS mutation status is a predictive biomarker for resistance to EGFR antibodies among mCRC pts, and is recommended for use by ASCO and the FDA. Little is known about the uptake of clinical recommendations in oncology practice. We sought to study the effect of ASCO and FDA guidelines on the use of EGFR antibodies among a commercially insured population. Methods: The LifeLink Health Plan Claims Database (formerly the PharMetrics Patient-Centric Database) was used to create a cohort of &gt;18 yo mCRC pts treated between 2004-2010. We identified treatment and diagnosis using ICD-9 or HCPCS (J) codes. We defined 1st-line therapy as any chemotherapy +/- bevacizumab given after the pt had a claim for mCRC, excluding pts treated with EGFR antibodies in the 1st line. 2nd-line therapy was defined as the initiation of a new chemotherapy agent (irinotecan/oxaliplatin) +/- EGFR antibody. We examined pts in two-month time intervals and calculated the fraction of pts in each interval who received EGFR antibody at any point beyond their 1st-line treatment. Chi 2 tests were used to compare treatment rates at the time points shown in the Table. Results: 5,099 pts received 2nd-line therapy of which 2,603 pts received an EGFR antibody. Median age was 61 years, with 57% males. 59% received an EGFR antibody as a single agent. The remainder received this in combination with one or more of the following agents: fluorouracil 13.5%, irinotecan 36.7%, oxaliplatin 3.9%, and bevacizumab 6.1%. Rates of EGFR antibody use are outlined in the Table. Conclusions: The utilization of EGFR antibodies for mCRC treatment decreased following the presentation of clinical trial data, publication of ASCO guidelines and FDA label change. These data suggest that oncologists respond rapidly to new evidence and professional guidelines, and readily accept the use of predictive biomarkers in clinical practice. [Table: see text]
LABORATORY PROBLEMS OF BLOOD TRANSFUSION
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Obesity
Authors: Calvin H. Plimpton
Journal: JAMA (1992)

With a subject like obesity and a text of this size, a favorable review might say that "this book is pleasingly plump and easily digestible." And, as fat is the major storage form of energy, this book could be a major store of information for students, practitioners, and investigators. It must be admitted that with 95 contributors and 66 chapters, there will be repetition, some avoidable. There will also be points of excellence and areas of token competence. But, here, the overall result is good and frequently very good. The book is handsomely bound, easily opens flat, and, in fact, would look good on any bookshelf. One turns eagerly to the initial section "Fat Metabolism" hoping for a clear and persuasive clarification of the muzziness we took out of medical school. "Intermediary Metabolism" has many useful descriptions but then weakens the thrust by frequently qualifying statements with "may" or "it
Lipoprotein(a) Measurement and Determining Risk of Myocardial Infarction—Reply
Authors: Pia R. Kamstrup
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Frauenfelder Straddles Border
Journal: Environmental Health Perspectives (1995)

hillsides."We have no idea why," said Morrison."It would just be wild speculation to give a reason."Mice belonging to this genus include deer mice, brush mice, and white-footed mice.They generally weigh about an ounce and are a few inches long.Morrison says his findings will be com- piled with those of researchers doing simi- lar studies in different geographical regions of the state to try to determine when hantavirus infection is highest in rodents and thus when it may most likely be spread to humans.With such information, people can be told to be careful in certain habitats or to avoid being near rodents during cer- tain times of year.Although the chances of contracting HPS are low, according to Levy, concern is high because one out of two people who get the disease die.For the present, Levy advises avoiding all contact with rodents and making sure homes are rodent-proofed by caulking and sealing holes and other possible entrances.
Defeating Schistosomiasis
Authors: Donald P. McManus
Journal: New England Journal of Medicine (2019)

Schistosomiasis is an ancient, neglected parasitic disease caused by blood flukes (trematode worms) of the genus schistosoma. Affecting an estimated 200 million persons in 78 countries, the disease is intimately associated with poverty and is grossly debilitating, leading to chronic ill health.1 The African species Schistosoma haematobium (urogenital) and S. mansoni (intestinal) have the highest prevalence and cause by far the greatest burden of disease (approximately 90% of which occurs in sub-Saharan Africa).1 Only one drug, praziquantel, is available to treat all forms of schistosomiasis, and it is widely used. The World Health Organization (WHO) sets ambitious targets for global . . .
Abstract 299: TAK1 signaling regulates p53 through a mechanism involving ribosomal stress
Authors: Andrei V. Bakin, Justin Zonneville, Vincent Wong
Journal: Cancer Research (2020)

Abstract Triple-negative breast cancer (TNBC) is among the most aggressive forms of breast cancer with limited therapeutic options. TAK1 is implicated in aggressive behavior of TNBC, while means are not fully understood. Here, we report that pharmacological blockade of TAK1 signaling hampered ribosome biogenesis (RBG) by reducing expression of RBG regulators such as RRS1, while not changing expression of ribosomal core proteins. Importantly, TAK1 blockade upregulated expression of p53 target genes in cell lines carrying wild type (wt) TP53 but not in p53-mutant cells. By examining involvement of the ribosomal stress response, we found that p53 activation by blockade of TAK1 was prevented by depletion of ribosomal protein RPL11. Further, siRNA-mediated depletion of TAK1 or RELA resulted in activation of p53 signaling and this response was dependent on RPL11. Knockdown of RRS1 disrupted nucleolar organization and resulted in activation of p53. Genomic TCGA data showed that TNBCs express high levels of ribosome biogenesis regulators, and elevated RRS1 levels correlate with unfavorable prognosis. Cytotoxicity data showed that TNBC cell lines are more sensitive to TAK1 inhibitor compared to luminal and HER2+ cell lines. Together, the data indicate that TAK1 regulates p53 activation by controlling ribosome biogenesis factors, and the TAK1-ribosome axis is a potential therapeutic target in TNBC. Citation Format: Andrei V. Bakin, Justin Zonneville, Vincent Wong. TAK1 signaling regulates p53 through a mechanism involving ribosomal stress [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 299.
Coccidioidal Meningitis
Authors: JEAN EDWARDS HOLT
Journal: Annals of Internal Medicine (1972)

Letters, Comments, and Corrections1 November 1972Coccidioidal MeningitisJEAN EDWARDS HOLT, M.D., JAMES E. GRAY, M.D., WILLIAM L. LERNER, M.D.JEAN EDWARDS HOLT, M.D.Search for more papers by this author, JAMES E. GRAY, M.D.Search for more papers by this author, WILLIAM L. LERNER, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-77-5-814_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: On our medical service we have a 20-year-old male patient with systemic lupus erythematosus (presently in remission) and, since treatment for this 2 years ago, chronic cryptococcal meningitis; he is now on his fourth course of amphotericin B therapy. One year ago, he had an Ommaya reservoir placed for intrathecal administration of therapy. We had discussed using the reservoir taps for observing his disease course. Simultaneous lumbar puncture and ventricular taps were performed for base-line studies. The lumbar-tap findings were opening pressure, 410 mm; glucose, 24 mg/100 ml; protein, 32 mg/100 ml; cells, 90 with 55% neutrophils.... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: JEAN EDWARDS HOLT, M.D.; JAMES E. GRAY, M.D.; WILLIAM L. LERNER, M.D.Affiliations: Department of Medicine University of Missouri Columbia, Mo. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 November 1972Volume 77, Issue 5Page: 814-814KeywordsAmphotericinCellsCryptococcal meningitisGlucoseLumbar punctureLupus erythematosusMedical servicesMeningitisNeutrophilsProteins ePublished: 1 December 2008 Issue Published: 1 November 1972 PDF downloadLoading ...
SENCAR Mouse Skin Tumorigenesis Model versus Other Strains and Stocks of Mice
Authors: Thomas J. Slaga
Journal: Environmental Health Perspectives (1986)

The SENCAR mouse stock was selectively bred for eight generations for sensitivity to skin tumor induction by the two-stage tumorigenesis protocol using 7,12-dimethylbenz(a)anthracene (DMBA) as the initiator and 12-O-tetradecanoylphorbol-13-acetate (TPA) as the promoter. The SENCAR mouse was derived by crossing Charles River CD-1 mice with skin-tumor-sensitive mice (STS). The SENCAR mice are much more sensitive to both DMBA tumor initiation and TPA tumor promotion than CD-1, BALB/c, and DBA/2 mice. An even greater difference in the sensitivity to two-stage skin tumorigenesis is apparent between SENCAR and C57BL/6 mice when using DMBA-TPA treatment. However, the SENCAR and C57BL/6 mice have a similar tumor response to DMBA-benzoyl peroxide treatment, suggesting that TPA is not an effective promoter in C57BL/6 mice. The DBA/2 mice respond in a similar manner to the SENCAR mice when using N-methyl-N-nitro-N-nitrosoguanidine (MNNG)-TPA treatment. The SENCAR mouse model provides a good dose-response relationship for many carcinogens used as tumor initiators and for many compounds used as tumor promoter. When compared to other stocks and strains of mice, the SENCAR mouse has one of the largest data bases for carcinogens and promoters.